ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections SYDNEY, Australia, March 15, 2022 (GLOBE NEWSWIRE) —  ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for

ITA Airways announces that it has signed a preliminary agreement with the maintenance company Atitech, for a service contract ROME, March 15, 2022 (GLOBE NEWSWIRE) — In relation to the tender for the acquisition of the maintenance business unit of Alitalia under Extraordinary Administration expiring today, 14 March 2022, ITA

Mexico has adopted the Codex international food safety authority’s specification for steviol glycosides Rancho Santa Margarita, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Sweegen’s entire Signature Bestevia® portfolio of nature-based sweeteners and sweetener systems is now accessible to brands in Mexico after the country’s food safety authority adopted the Codex

Sustainable hot melt adhesives resolve manufacturers from traditional hurdles in bonding Bedford, Mass., March 15, 2022 (GLOBE NEWSWIRE) — A new era for adhesives has arrived for manufacturers seeking debondable structural adhesive solutions to avoid waste and save costs in manufacturing. Today, Conagen, the biotechnology innovator, announced the development of

Grid-eMotion™ Fleet smart charging solution to help the City of Berlin reach its goal of a zero-emission bus fleet by 2030 Zurich, Switzerland, March 15, 2022 (GLOBE NEWSWIRE) — Hitachi Energy has won an order from Berliner Verkehrsbe-triebe (BVG), Germany’s biggest municipal public transportation company, to supply its Grid-eMotion™ Fleet

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts  First clinical data demonstrating effectiveness of HGNS to treat CCC patients  As previously disclosed, confirms achievement of primary endpoint of AHI4 reductions for entire population, CCC cohort, and non-CCC cohort at six months, and reports 60%+ responder rates for all three